References
- Devonshire IM, Papadakis NG, Port M, et al. Neurovascular coupling is brain region-dependent. Neuroimage 2012;59:1997-2006
- Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2011;18:69-77
- Begley CE, Famulari M, Annegers JF, et al. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia 2000;41:342-51
- Pugliatti M, Beghi E, Forsgren L, et al. Estimating the cost of epilepsy in Europe: a review with economic modeling. Epilepsia 2007;48:2224-33
- Semah F, Picot MC, Adam C, et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 1998;51:1256-62
- Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Eng J Med 2000;342:314-9
- Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on? Seizure 2000;9:464-8
- Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010;51:1069-77
- Cramer JA. Quality of life for people with epilepsy. Neurol Clin 1994;12:1-13
- Nei M, Bagla R. Seizure-related injury and death. Curr Neurol Neurosci Rep 2007;7:335-41
- Nilsson L, Ahlbom A, Farahmand BY, et al. Risk factors for suicide in epilepsy: a case control study. Epilepsia 2002;43:644-51
- Murray MI, Halpern MT, Leppik IE. Cost of refractory epilepsy in adults in the USA. Epilepsy Res 1996;23:139-48
- Yoon D, Frick KD, Carr DA, et al. Economic impact of epilepsy in the United States. Epilepsia 2009;50:2186-91
- Ivanova JI, Birnbaum HG, Kidolezi Y, et al. Economic burden of epilepsy among the privately insured in the US. Pharmacoeconomics 2010;28:675-85.
- Kurth T, Lewis BE, Walker AM. Health care resource utilization in patients with active epilepsy. Epilepsia 2010;51:874-82
- Ivanova JI, Birnbaum HG, Kidolezi Y, et al. Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States. Epilepsia 2010;51:838-44
- Lee WC, Arcona S, Thomas SK, et al. Effect of comorbidities on medical care use and cost among refractory patients with partial seizure disorder. Epilepsy Behav 2005;7:123-6
- Lee WC, Hoffmann MS, Arcona S, et al. A cost comparison of alternative regimens for treatment-refractory partial seizure disorder: an econometric analysis. Clin Ther 2005;27:1629-38
- Davis KL, Candrilli SD, Edin HM. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Epilepsia 2008;49:446-54
- Ettinger AB, Manjunath R, Candrilli SD, et al. Prevalence and cost of nonadherence to antiepileptic drugs in elderly patients with epilepsy. Epilepsy Behav 2009;14:324-9
- Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245-51
- Ross AP. Tolerability, adherence, and patient outcomes. Neurology 2008;71:S21-3